HOTH THERAPEUTICS - Key Persons

Adam Friedman, M.D., F.A.A.D. is Professor and Interim Chair of Dermatology and serves as Residency Program Director and Director of Translational Research in the Department of Dermatology at The George Washington University School of Medicine & Health Sciences. Dr. Friedman completed his undergraduate training at the University of Pennsylvania and graduated with Distinction in Dermatologic Research at the Albert Einstein College of Medicine in New York. He completed his internship at New York Hospital Queens and returned to Einstein for his Dermatology residency, where he was appointed Chief Resident during his final year. Dr. Friedman joined the Einstein faculty after graduation and served as the Director of Dermatologic Research, Director of the Translational Research Fellowship, and the Associate Program Director.

Job Titles:

• Associate Professor in the Psychiatry Department at Washington University School of Medicine

Carla Yuede, Ph.D. is an Associate Professor in the Psychiatry Department at Washington University School of Medicine in St. Louis, MO. She graduated from Missouri State University in 2000 with a BS in Psychology and Biomedical Science, and received her Ph.D in Behavioral Neuroscience at the University of Missouri - St. Louis. During graduate school, she began a collaboration with the newly formed Animal Behavior Core (ABC) at Washington University and completed her dissertation research on the long-term behavioral effects of neonatal NMDA receptor antagonism under the guidance of Dr. David Wozniak (Psychiatry) in the lab of Dr. John Olney (Psychiatry). Following graduation, she completed a postdoc studying the effects of stress on Alzheimer's disease pathology with Dr. John Csernansky (Psychiatry). In 2012, she became faculty in the Neurology department at Washington University working with Dr. John Cirrito to develop micro-immunoelectrodes (MIEs) to study rapid kinetics of beta amyloid and other peptides involved in Alzheimer's disease. With the Cirrito lab, the MIE technology has been optimized and expanded to detect several different proteins and peptides, including SARS-CoV-2. Dr. Yuede is currently the Director of the Animal Behavior Core Laboratory at Washington University. The Animal Behavior Core Lab routinely conducts functional assessment analyses on a wide range of pre-clinical rodent models. The lab focuses on behavioral tests in six functional domains: 1) sensorimotor functions; 2) learning and memory; 3) altered emotionality; 4) social behaviors and interactions; and 5) sensory-based behaviors, to examine the behavioral consequences of gene mutations as well as assess the effects of specific drugs, experimental manipulations (e.g., neuronal loss, stress), or altered development on behavior in laboratory rodents. Dr. Yuede's primary research focus is on the mechanisms underlying biological/physiological changes occurring in the brain leading to impairments or improvements in memory function.

Job Titles:

• Director
• Founder and Principal of Sarnoff Group

David Sarnoff has served as a director of the Company since August 2018. Since June 2015, Mr. Sarnoff has served as the founder and Principal of Sarnoff Group, LLC, and since January 2019, he has served as the Director of Strategic Partnerships and Executive Leadership Coach at Loeb Leadership. In addition, since December 2021, Mr. Sarnoff has served as Adjunct Faculty at iCoach New York with respect to a professional coaching program. From October 2003 until June 2015, Mr. Sarnoff served as the co-founder and Principal of Morandi, Taub & Sarnoff LLC, an executive search firm, and from July 1998 until October 2003 he served as a Legal Recruiter for Schneider Legal Search, Inc. From August 1994 until July 1998, Mr. Sarnoff served as a litigation associate attorney at Wachtel Missry LLP (formerly known as Gold & Wachtel LLP). Since July 2018, Mr. Sarnoff has served as a member of the advisory committee of the New Jersey Association of School Resource Officers. From January 2015 until January 2018, Mr. Sarnoff served as board President of Fort Lee Board of Education and served as a board member from January 2013 through January 2019. In September of 2020, Mr. Sarnoff was appointed to a three year term on the Diversity, Equity & Inclusion Committee of the New York City Bar Association. Mr. Sarnoff received his Juris Doctor from Rutgers University School of Law and his bachelor of arts from Hofstra University. Mr. Sarnoff is admitted to the New York and New Jersey (retired status) state bars.

Job Titles:

• Chief Financial Officer

David Briones has served as Chief Financial Officer of the Company since March 2019 and has over nineteen years of public accounting and executive level experience. He consults with various public companies in financial reporting, internal control development and evaluation, budgeting and forecasting. Since September 2021, Mr. Briones has served as Chief Financial Officer, Treasurer and Secretary and a member of the board of directors of Larkspur Healthcare Acquisition Corp. (Nasdaq: LSPR), a special purpose acquisition corporation. Since October 2010, he has served as the managing member and founder of Brio Financial Group, LLC, a full-service financial consulting firm that brings experienced finance and accounting expertise to both public and private companies. Since 2010, Mr. Briones has served over 75 companies as well as numerous banks, hedge funds, venture capital funds and private equity firms. In addition, from May 2018 until its dissolution in April 2021, Mr. Briones served as Executive Chair of Zovis Pharmaceuticals, and from August 2013 to January 2020, Mr. Briones served as Chief Financial Officer of Petro River Oil Corp. ("PTRC"), an independent energy company focused on the exploration and development of conventional oil and gas assets. Mr. Briones also served as interim Chief Financial Officer of AdiTx Therapeutics, Inc. (Nasdaq: ADTX), a pre-clinical stage, life sciences company with a mission to prolong life and enhance life quality of transplanted patients from January 2018 to July 2020 (until the company's initial public offering). From October 2017 to May 2018, Mr. Briones served as the Chief Financial Officer of Bitzumi, Inc., a Bitcoin exchange and marketplace. Prior to founding Brio Financial Group, LLC, Mr. Briones was an auditor with Bartolomei Pucciarelli, LLC in Lawrenceville, New Jersey and PricewaterhouseCoopers LLP in New York, New York. Since May 2020, Mr. Briones has served as a member of the board of directors of Unique Logistics International Inc (OTC Pink: UNQL). Mr. Briones received a bachelors of science degree in accounting from Fairfield University.

Dr. Glenn Cruse, PhD, is currently Assistant Professor of Immunology at North Carolina State University within the College of Veterinary Medicine. Dr. Cruse completed his graduate studies at Glenfield Hospital, of the University of Leicester, United Kingdom, where he focused on human lung mast cell biology in asthma. He completed his postdoctoral fellowship training in the Laboratory of Allergic Diseases, NIAID at NIH before starting his own research program in his current position at NC State. The goal of his research program is to establish novel regulators of allergic inflammation and to develop targeted therapeutics for allergic inflammation and mast cell-mediated diseases.

Job Titles:

• Associate Professor of Neurology at Washington University School of Medicine

Dr. John Cirrito is an Associate Professor of Neurology at Washington University School of Medicine in St. Louis, MO. He received his B.A. in psychology from Boston College where he worked with Dr. Michael Numan (Psychology) studying the neural circuits underlying maternal avoidance in rats. He graduated in 1998 and spent a year working in Research and Development at NEN Life Sciences developing research reagents, including some that his own lab still uses. In 1999 he started his PhD in Neuroscience at Washington University, St. Louis in the lab of Dr. David Holtzman (Neurology) studying Alzheimer's disease. Much of his PhD work focused on the proteins and cellular pathways that eliminate amyloid-beta (Aβ) from the brain. Here he developed the first use of in vivo microdialysis to study Aβ kinetics in the brain of a living mouse. This was the first time someone was able to measure AD-related proteins longitudinally in the brain of a living animal. His group has since adapted the technique to measure a variety of protein kinetics to understand the positive and negative impact of risk factors on Alzheimer's disease. In the Holtzman lab he realized the importance and value of collaboration, having worked with numerous departments across the university as well as outside groups and industries. Dr. Cirrito received his PhD in 2005, then became a post-doc in the lab of Dr. Steven Mennerick (Psychiatry) studying the synaptic processes that regulate Aβ generation. He started his own laboratory (Neurology) at Washington University in 2010, received tenure in 2015, and serves on more committees and review panels than he wishes to think about. His group studies how neuronal activity regulates metabolism of AD-related proteins, including the basic science of how neurotransmitter signaling impacts A and tau generation, as well how complex behaviors such as stress and sleep could impact disease risk differentially between males and females. His group pioneered the use of a micro-immunoelectrode (MIE) technology to measure A and tau protein levels on a minute-to-minute timescale in a living mouse brain. As a consequence of the COVID pandemic, Dr. Cirrito's group is now adapting the MIE for detection of aerosolized SARS-COV-2 viral particles in the breath and the environment for near instantaneous diagnostic and surveillance of positive cases.

Job Titles:

• Professor of Chemical and Life Science Engineering at Virginia Commonwealth University

Dr. Michael Peters is currently Professor of Chemical and Life Science Engineering at Virginia Commonwealth University. He is also an Associate Member of VCU's Massey Cancer Center and an affiliated faculty in the Department of Anatomy and Neurobiology. Dr. Peters received his PhD from the Ohio State University in 1981 and his B.S from the University of Dayton in 1977. Dr. Peters teaches across a broad spectrum of courses in mathematics, science, engineering, and medicine, was involved in the teaching of medical school gross anatomy for over 15 years, trained in animal surgical methods, and has held both academic and clinical appointments. Dr. Peters bioengineering research spans from fundamental to applied studies merging detailed biomolecular computations and mathematical methods to experimental studies, including preclinical and laboratory experiments. His fundamental research includes protein structure, function and interactions, protein folding, and fragment-based protein engineering methods. Current applied studies include inhibition strategies against the SARS-Cov-2 spike protein, amyloid fibril therapeutics in the treatment of AD, and inhibitor design and development for the HSP70-Bag-1 anti-apoptotic pathway in a variety of chemoresistant cancers.

Job Titles:

• Director

Graig Springer has served as a director of the Company since February 2020. Since April 2021, Mr. Springer has served as Vice President for Brookfield Asset Management Inc. ("Brookfield") in their Legal and Regulatory Department ,and from August 2020 to April 2021, he served as a consultant to Brookfield. From May 2019 to August 2019, Mr. Springer assisted with product development and governance at Invesco U.S., an investment management company, and from December 2013 to May 2019, he served in various capacities at OppenheimerFunds, Inc., an investment management company acquired by Invesco U.S., including distribution compliance and product development. In addition, Mr. Springer served on the Sub-Adviser Oversight Committee at OppenheimerFunds, Inc. Mr. Springer received his bachelor of arts from Columbia University and his Juris Doctor from Fordham University School of Law. Mr. Springer also holds a Series 7 and a Series 24 license.

Job Titles:

• Executive Vice President
• Executive Vice President Operations

Hayley Springer joined the Hoth Therapeutics team in December 2017 as Vice President of Operations and was promoted to Executive Vice President in May 2022. Ms. Springer has spent the bulk of her career in operational management helping smaller companies stay on budget and on track for business development goals and milestones. Prior to joining Hoth, Ms. Springer worked in various office, executive and administrative positions for over 15 years, including most recently another small cap biotech company and a family office. Ms. Springer received her Bachelors of Science from Brigham Young University and received a Continuing Education Certificate in Accounting from NYU as well as completed Rutgers Business School's Mini-MBA program in BioPharma Innovation.

Job Titles:

• Director
• Chief of Rehabilitation Medicine at Englewood Health

Jeff Pavell has served as a director of the Company since December 2022. Since January 2017, Dr. Pavell has served as Chief of Rehabilitation Medicine at Englewood Health, and since November 2005, he has been on the teaching staff at New York-Presbyterian Columbia University Irving Medical Center. In addition, since December 2020 he has been on the teaching staff at Hackensack Meridian School of Medicine at Seton Hall. Furthermore, since 2010, Dr. Pavell has served as a partner at Patient Care Associates, an outpatient surgical center, and since 2002, he has served as a Partner at the Physical Medicine and Rehabilitation Center, a private medical practice serving patients with spine, sports and occupational injuries. Dr. Pavell is a Board Certified physician specializing in the field of physical medicine and rehabilitation. Dr. Pavell is also certified in pain medicine and specializes in the most advanced non-operative treatments for spine, sports and interventional pain medicines. Dr. Pavell received his bachelor of arts from Johns Hopkins University and his D.O. degree with honors from the New York College of Osteopathic Medicine. Since January 2021, Dr. Pavell has served as a member of the board of directors as well as chairman of the audit committee and a member of the compensation committee of FoxWayne, a special purpose acquisition corporation. Furthermore, since September 2022, Dr. Pavell has served as a director of Silo Pharma, Inc. (Nasdaq: SILO) ("Silo") as well as a member of the audit committee, compensation committee and chair of the nominating and corporate governance committee of Silo.

Jonathan Zippin MD, PhD attended Cornell University where he received a Bachelor's of Science with Honors. He then attended the Rockefeller/Cornell/Sloan-Kettering Tri-Institutional MD/PhD program. He completed his general medicine internship at the Mount Sinai Hospital in New York City, followed by a residency in dermatology at the Weill Cornell Medical Center - New York Presbyterian Hospital. Dr. Zippin is an Associate Attending Dermatologist and Associate Professor of Dermatology and Pharmacology at Weill Medical College of Cornell, and is the Vice Chair of Research for the Department of Dermatology. For the past 18 years, he has helped to establish the role of distinct cAMP microdomains in mammalian cell biology and revealed new mechanisms in insulin release and cancer. For the past ten years, Dr. Zippin's laboratory has been dedicated to understanding the role of cAMP microdomains in skin disease. Dr. Zippin has served as a consultant for numerous pharmaceutical companies including Pfizer and Cellgene. He is also the founder of a biotechnology company that is developing antibody based diagnostics for cancer. Dr. Zippin has published numerous peer-reviewed papers and book chapters and serves on the board of multiple scientific societies.

Job Titles:

• Attending Physician

Dr. Lacouture is an Attending Physician and the director of the Oncodermatology Program in the Dermatology Service, Department of Medicine, at Memorial Sloan Kettering Cancer Center and a Professor in the Department of Dermatology, Weill Cornell Medicine in New York City. He did his postdoctoral work at Brigham and Women's Hospital in Boston, MA, an internship in General Surgery at Cleveland Clinic and residency in dermatology at The University of Chicago, IL. He received his M.D. degree from Javeriana University in Bogota, Colombia, where he grew up. He pioneered the discipline of Oncodermatology, which studies and treats dermatologic conditions in cancer patients, and those that arise as a consequence of chemotherapy and/or radiotherapy or stem cell transplants. Dr. Lacouture is currently the Principal Investigator for "The CHANCE Trial", A Longitudinal Study of Chemotherapy-Induced Hair Changes and Alopecia, Skin Aging and Nail Changes in Women with Non-Metastatic Breast Cancer and a NIH funded study to identify the mechanisms of immune-related cutaneous adverse events. In addition, Dr Lacouture is the principal investigator for various therapeutic trials in oncodermatology. Dr. Lacouture is a well-known lecturer in the US and abroad on dermatologic conditions as a result of cancer therapies. He founded a clinical program that encompasses patient care, education, and research on dermatologic care in cancer patients and survivors. He is the founder of the Oncodermatology and Immunotherapy Study Group of the Multinational Association of Supportive Care in Cancer and is on the advisory board of Cancer.Net. In 2012, CancerCare named Dr Lacouture as Physician of the Year for his contributions to the education of people living with cancer, and he has been rated as a Top Doctor by New York Magazine since 2012. In 2021 he was awarded the Everett C. Fox Memorial Lectureship by the American Academy of Dermatology for his innovative work in oncodermatology. Dr Lacouture has published over 260 articles in peer-reviewed journals and is the author of Dr Lacouture's Skin Care Guide for People Living With Cancer and Editor of the textbook Dermatologic Principles and Practice in Oncology.

Job Titles:

• Chairman of the Board
• Chief Executive Officer
• Founder
• President

Robb Knie has served as President and Chief Executive Officer and as a director of the Company since May 2017 and served as our principal financial and accounting officer from June 2018 until March 2019. Since October 15, 2020, Mr. Knie has served as the Chief Executive Officer, Chief Financial Officer and chairman of the board of directors of FoxWayne Enterprises Acquisition Corp. (Nasdaq: FOXW). Mr. Knie served as the President of Lifeline Industries Inc. since its inception in 1995. From 2002 to 2010 he was a Semiconductor Analyst for PAW Partners. From 1993 until 1995, Mr. Knie served as Northeast Regional Manager of American Express Financial Advisors. Mr. Knie has served as a board member for Nasdaq-listed companies. He has been featured on Bloomberg, The Wall Street Journal and Forbes Magazine as an Independent Equity Analyst. Mr. Knie has over 20 years of equity markets experience. Mr. Knie has been a member of the American Chemical Society, Institute of Electrical and Electronics Engineers, as well as The National Alliance for Youth Sports.

Job Titles:

• Director

Wayne D. Linsley has served as a director of the Company since April 2020. Mr. Linsley has been in business management for over 40 years. He possesses a wide and varied skillset including sales and sales management, finance (for both public and private companies), accounting, audit support and financial reporting. He has a bachelor's in business administration from Siena College in Loudonville, NY. From 2009 to September 2021 he worked for a financial reporting firm that works with publicly traded companies. He has extensive knowledge of financial statements, MD&A, SEC Filings (10-K, 10-Q, 8-K, etc.) Edgar, etc. He often negotiated on behalf of clients in such areas as audit fees, transfer agents, Edgar companies, etc. He currently serves as an independent director for DatChat Inc. (Nasdaq: DATS), serving the chair of its audit committee, compensation committee and nominating and corporate governance committee, and Silo Pharma, Inc. (OTCQB: SILO).

William Weglicki, MD trained in Medicine at the Georgetown University Hospital before completing his cardiology fellowship at Duke University Medical Center. After two years as a Research Associate at NIH and Johns Hopkins University, he joined the faculty of Harvard Medical School for seven years and there he was promoted to Associate Professor of Medicine. In 1975 he was appointed Chairman of the Department of Biophysics at the Medical College of Virginia of Virginia Commonwealth University. While at Harvard and MCV he was awarded several NIH research grants. At the Oklahoma Medical Research Foundation he led their Cardiovascular Research Program. He joined the George Washington University Department of Medicine in 1985 and formed the Division of Experimental Medicine; in 1987 this core group of investigators was awarded a Program Project grant on Molecular Mechanisms of Cardiovascular Injury from the National Heart, Lung and Blood Institute. For 12 years he served as chairman of the Department of Physiology at GWU. From 2002 -2006 he served as President of the US, Canada, Mexico Section of the International Society for Heart Research. In 2005 he organized a symposium for the WHO on magnesium and disease processes. In 2006 he was an invited chair and speaker at the International Magnesium Society meeting in Japan. He chaired the Gordon Conference on Magnesium in Biochemical Processes and Medicine in 2008 in California. He has been a principal investigator on NHLBI research grants for more than 30 years. From 2014-2018 at GWU he served as Interim Chair of the Department of Biochemistry and Molecular Medicine. His ongoing research includes the study of cardiac and cutaneous side effects due to some of the EGFR/Tyrosine Kinase Inhibiting anticancer drugs.